21255-1-AP
antibody from Proteintech Group
Targeting: IL36G
IL-1F9, IL-1H1, IL-1RP2, IL1E, IL1F9, IL1H1
Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 21255-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- IL-36 Gamma antibody
- Antibody type
- Polyclonal
- Description
- IL-36 Gamma antibody (Cat. #21255-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references IL36 indicating good prognosis in human Hepatocellular Carcinoma.
Tacrolimus Inhibits TNF-α/IL-17A-Produced pro-Inflammatory Effect on Human Keratinocytes by Regulating IκBζ.
IL-36γ is a pivotal inflammatory player in periodontitis-associated bone loss.
Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.
Hu M, Tong Y, Fang H, Tang J, Liu L, Hu Y, Li J, Zhong L
Journal of Cancer 2020;11(21):6248-6255
Journal of Cancer 2020;11(21):6248-6255
Tacrolimus Inhibits TNF-α/IL-17A-Produced pro-Inflammatory Effect on Human Keratinocytes by Regulating IκBζ.
Hu Y, Guo J, Yin L, Tu J, Yin Z
Inflammation 2020 Apr;43(2):692-700
Inflammation 2020 Apr;43(2):692-700
IL-36γ is a pivotal inflammatory player in periodontitis-associated bone loss.
Cloitre A, Halgand B, Sourice S, Caillon J, Huck O, Bugueno IM, Batool F, Guicheux J, Geoffroy V, Lesclous P
Scientific reports 2019 Dec 17;9(1):19257
Scientific reports 2019 Dec 17;9(1):19257
Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.
Boutet MA, Bart G, Penhoat M, Amiaud J, Brulin B, Charrier C, Morel F, Lecron JC, Rolli-Derkinderen M, Bourreille A, Vigne S, Gabay C, Palmer G, Le Goff B, Blanchard F
Clinical and experimental immunology 2016 May;184(2):159-73
Clinical and experimental immunology 2016 May;184(2):159-73
No comments: Submit comment
No validations: Submit validation data